首页> 美国卫生研究院文献>American Journal of Human Genetics >Identification of a Novel Risk Locus for Progressive Supranuclear Palsy by a Pooled Genomewide Scan of 500288 Single-Nucleotide Polymorphisms
【2h】

Identification of a Novel Risk Locus for Progressive Supranuclear Palsy by a Pooled Genomewide Scan of 500288 Single-Nucleotide Polymorphisms

机译:通过汇集全基因组扫描的500288单核苷酸多态性确定进行性核上性麻痹的新型风险源。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

To date, only the H1 MAPT haplotype has been consistently associated with risk of developing the neurodegenerative disease progressive supranuclear palsy (PSP). We hypothesized that additional genetic loci may be involved in conferring risk of PSP that could be identified through a pooling-based genomewide association study of >500,000 SNPs. Candidate SNPs with large differences in allelic frequency were identified by ranking all SNPs by their probe-intensity difference between cohorts. The MAPT H1 haplotype was strongly detected by this methodology, as was a second major locus on chromosome 11p12-p11 that showed evidence of association at allelic (P<.001), genotypic (P<.001), and haplotypic (P<.001) levels and was narrowed to a single haplotype block containing the DNA damage-binding protein 2 (DDB2) and lysosomal acid phosphatase 2 (ACP2) genes. Since DNA damage and lysosomal dysfunction have been implicated in aging and neurodegenerative processes, both genes are viable candidates for conferring risk of disease.
机译:迄今为止,只有H1 MAPT单倍型一直与发展神经退行性疾病进行性核上性麻痹(PSP)的风险相关。我们假设额外的基因位点可能与赋予PSP风险有关,这可以通过基于池的全基因组关联研究> 500,000个SNP来确定。等位基因频率差异较大的候选SNP通过根据队列之间探针强度差异对所有SNP进行排名来确定。通过这种方法可以强烈检测到MAPT H1单倍型,染色体11p12-p11上的第二个主要基因座也显示出等位基因(P <.001),基因型(P <.001)和单倍型(P <。 001)水平,并缩小到包含DNA损伤结合蛋白2(DDB2)和溶酶体酸性磷酸酶2(ACP2)基因的单倍型区域。由于DNA损伤和溶酶体功能障碍与衰老和神经退行性过程有关,因此这两个基因都是可能的疾病风险候选者。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号